PBAC's latest decision on Coal tar prepared: Recommended (2014). Considered for Treatment of psoriasis. Scytera® Foam provides coal tar in a foam formulation designed to improve patient adherence through easier application and cosmetic acceptability.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2005
Submissions
2
2005 → 2014
Eligible population
Patients with psoriasis requiring topical coal tar therapy.
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Other
Comparator
Exorex™ (coal tar prepared 1% lotion)
Economic model
Cost-minimisation
Budget impact
$10M
ICER note
Not modelled; this is a minor submission (formulation change/cost-minimisation). No economic evaluation was conducted.